Clinical trials: Neoadjuvant Treatment
Head and Neck Squamous Cell Carcinoma
Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC
A phase Ⅱ open label multi-cencter clinical trail to evaluate the efficacy and safety of pembrolizumab combined with low-dose PF (cisplatin + 5-fluorouracil) in the neoadjuvant treatment of locally advanced head and neck squamous…
- Trial name
- NCT05446467
- Testing
- pembrolizumab+cisplatin + 5-FU
- Where
- 7 sites in China
- Volunteers
- 80 people
- Sponsor
- Zhejiang Provincial People's Hospital
Esophageal Squamous Cell Carcinoma
Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage Ⅱ-Ⅲ Esophageal Cancer Patients
The purpose of this study is to evaluate the efficacy and safety of neoadjuvant chemotherapy with nab-paclitaxel plus cisplatin for stage Ⅱ-Ⅲ esophageal squamous cell carcinoma patients.
- Trial name
- nabPCESCC (NCT01258192)
- Testing
- albumin-bound paclitaxel plus cisplatin
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Zhejiang Cancer Hospital
Hepatocellular Carcinoma
Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial
Following the results of study IMbrave150, the combination Atezolizumab + Bevacizumab is a promising treatment option for patients with HCC.
- Trial name
- AB-LATE02 (NCT04727307)
- Testing
- Atezolizumab (neoadjuvant), Percutaneous Radiofrequency, Bevacizumab (adjuvant)
- Where
- 19 sites in France
- Volunteers
- 202 people
- Sponsor
- University Hospital, Montpellier
Chemotherapy Induced Peripheral Neuropathy (CIPN)
Neoadjuvant FOLFOX Chemotherapy for Colon Cancer: Long-Term Chemotherapy-Induced Peripheral Neuropathy and Impact on Quality of Life
The goal of this observational study was to learn about the long-term effects of neoadjuvant (pre-surgery) chemotherapy on patients with locally advanced colon cancer.
- Trial name
- NEOCIPN-COLON (NCT06844409)
- Where
- Russia
- Volunteers
- 54 people
- Sponsor
- P. Herzen Moscow Oncology Research Institute
Carcinoma Cervix
Study on Early Stage Bulky Cervical Cancers
The aim of this study is to establish the role of neoadjuvant chemotherapy and chemo irradiation in carcinoma cervix and to compare its results with the concurrent chemo irradiation in terms of overall survival, disease free…
- Trial name
- NCT01917695
- Testing
- Chemotherapy, External Beam Radiotherapy, Brachytherapy
- Where
- India
- Volunteers
- 180 people
- Sponsor
- Rajkumar Kottayasamy Seenivasagam
Biliary Tract Cancer
Gemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract Malignancies
This trial is to evaluate the efficacy of Gemcitabine-Cisplatin (GC) plus Envafolimab neoadjuvant therapy in the patients at high risk of recurrence. Primary endpoint: Major Pathologic Response (MPR).
- Trial name
- GENE (NCT07599995)
- Testing
- Neoadjuvant therapy followed by surgery
- Volunteers
- 34 people
- Sponsor
- Sir Run Run Shaw Hospital
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma
The purpose of this study is to assess whether the addition of the immune checkpoint inhibitor Nivolumab to induction chemotherapy will increase the percentage of patients with a complete response on MRI and PET after 3 cycles of…
- Conditions
- Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharyngeal Neoplasms, Nasopharynx Cancer
- Trial name
- NPC-Nivo (NCT06019130)
- Testing
- Nivolumab, Cisplatin, 5-Fluorouracil
- Where
- 31 sites in Germany
- Volunteers
- 57 people
- Sponsor
- German Society for Pediatric Oncology and Hematology GPOH gGmbH
Breast Neoplasms, Lipid Profile
Chemotherapy-induced Lipid Profile Changes in Women With Early Breast Cancer
Detection of changes in the lipid profile in early-stage breast cancer patients undergoing neoadjuvant or adjuvant chemotherapy with doxorubicin, cyclophosphamide, and paclitaxel.
- Conditions
- Breast Neoplasms, Lipid Profile, Dyslipidemia
- Trial name
- NCT06958783
- Testing
- Blood lipid monitoring in breast cancer patients during chemotherapy
- Where
- Slovakia
- Volunteers
- 56 people
- Sponsor
- Cancer center Stefan Kukura Hospital Michalovce
Breast Cancer, Breast Neoplasms
Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer
This is a Phase II, randomized, open-label trial to evaluate the clinical and immunologic activity of pembrolizumab plus chemotherapy when combined with various immunotherapy induction regimens as neoadjuvant therapy for triple…
- Trial name
- NCT04373031
- Testing
- Pembrolizumab, IRX 2
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Providence Health & Services
Glioblastoma
Neoadjuvant Temozolomide Combined With Simultaneous IMRT for Treatment of Glioblastoma
This study is a prospective, multi-center, randomized controlled clinical study. Indications: Glioblastoma diagnosed after surgery (WHO grade IV).
- Trial name
- NCT04829097
- Testing
- Temozolomide
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Rectal Cancer, Rectal Cancer Patients
Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial
Neoadjuvant fluoropyrimidine-based chemoradiotherapy followed by total mesorectal excision (TME) is the standard of care for locally advanced rectal cancer (LARC); however, pathologic complete response (pCR) rates are low.
- Trial name
- NCT06850090
- Testing
- TAS-102, Capecitabine
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Shandong Cancer Hospital and Institute
Breast Cancer
The Efficacy and Safety of Neoadjuvant Trastuzumab Plus Taxane With and Without Pertuzumab Therapy
This study is a Non-Interventional Study (NIS) with secondary data usage. It is designed as a multi-center retrospective cohort study in which the data of adult locally advanced HER2-positive breast cancer patients, who are…
- Trial name
- HER2PATH (NCT04765124)
- Where
- Turkey (Türkiye)
- Volunteers
- 1,500 people
- Sponsor
- Ahmet Bilici
Mibc, Muscle Invasive Bladder Cancer
Sasanlimab As Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized Muscle Invasive Bladder Cancer Patients
Selective Bladder-Sparing Trial with Sasanlimab as Maintenance Treatment Based On Clinical Response To Neoadjuvant Treatment In Molecularly Categorized Muscle Invasive Bladder Cancer Patients
- Trial name
- SASAN-SPARING (NCT06623162)
- Testing
- gemcitabine + cisplatine
- Where
- Spain
- Volunteers
- 70 people
- Sponsor
- Fundación de investigación HM
Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma
SIRT With Tremelimumab and Durvalumab for Resectable HCC
The goal of this research study is to evaluate the safety and tolerability of tremelimumab and durvalumab with or without Selective Internal Yttrium-90 Radioembolization (SIRT) in participants with resectable hepatocellular…
- Conditions
- Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer
- Trial name
- NCT05701488
- Testing
- Durvalumab, Tremelimumab, SIRT
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Jiping Wang, MD, PhD
Envafolimab Combined With Chemoradiotherapy in the Treatment of Locally Advanced pMMR/MSS Rectal Cancer
Single-arm, Single-center, Exploratory Phase II Clinical Study of Envafolimab Combined With Chemoradiotherapy in the Treatment of Locally Advanced pMMR/MSS Rectal Cancer
Preoperative radiotherapy combined with 5-fluorouracil/capecitabine is currently the standard treatment for locally advanced rectal cancer.
- Trial name
- ESTIMATE (NCT06239870)
- Testing
- Envafolimab combined with chemoradiotherapy in the whole course of neoadjuvant therapy
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Yunnan Cancer Hospital
Non-small Cell Lung Cancer, PDL1 Gene Mutation
Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study.
The goal of this clinical trial is to observe the efficacy and safety of Serplulimab monotherapy as a neoadjuvant treatment for TPS ≥ 50% non-small cell lung cancer (NSCLC).
- Trial name
- NSCLC (NCT06195683)
- Testing
- Serplulimab
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Zhejiang Cancer Hospital
Melanoma Stage III, Melanoma
Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
Subjects with resectable melanoma will receive neoadjuvant nivolumab followed by surgical resection. Post-operatively, subjects will receive open-label treatment with up to 1 year of adjuvant nivolumab or ipilimumab plus…
- Trial name
- NCT04013854
- Testing
- nivolumab, Ipilimumab
- Where
- 3 sites in United States
- Volunteers
- 67 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage II Gastric Cancer AJCC v8
Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers
This phase I trial tests the safety, side effects studies chemotherapy followed by chemotherapy at the same time as radiation therapy (chemoradiation) before surgery (neoadjuvant) in treating patients with stage gastric (stomach)…
- Conditions
- Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage IIA Gastric Cancer AJCC v8, Clinical Stage IIB Gastric Cancer AJCC v8
- Trial name
- NCT05296005
- Testing
- Capecitabine, Docetaxel, Fluorouracil
- Sponsor
- Ohio State University Comprehensive Cancer Center
Melanoma (Skin), Melanoma Stage IIIb-IVM1a
Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma
This study will investigate whether the use of talimogene laherparepvec (T-VEC) in combination with BRAF/MEK inhibitor will result in durable regional and distant recurrence free survival in the neoadjuvant setting for treatment…
- Conditions
- Melanoma (Skin), Melanoma Stage IIIb-IVM1a, Metastasis Skin, Tumor Skin
- Trial name
- NCT03972046
- Testing
- Talimogene laherparepvec (T-Vec), Dabrafenib (BRAF Inhibitor), Trametinib (MEK Inhibitor)
- Where
- United States
- Sponsor
- TriHealth Inc.
HR+/HER2+ Early Breast Cancer
Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer
This prospective, response-adapted phase II study evaluates the efficacy and safety of neoadjuvant fovinaciclib in combination with aromatase inhibitors and dual HER2 blockade in patients with HR-positive/HER2-positive early…
- Trial name
- TAYLOR-003 (NCT07616427)
- Testing
- Fovinaciclib, Aromatase Inhibitors, Trastuzumab + Pertuzumab
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.